ESR1 and breast carcinoma: E4 was also evaluated in combination with progesterone or drospirenone (DRSP) using three complementary endocrine-sensitive breast cancer models [60]: transgenic MMTV-PyMT mice, human MCF7 cell xenografts, and ER + breast cancer PDXs.